Polycyclic aromatic hydrocarbons (PAHs) are well-known and established environmental contaminants with a range of sources to the environment ([@kfx035-B38]; [@kfx035-B78]). Exposure to PAHs has been linked with a range of health effects, including cancer and developmental challenges ([@kfx035-B5]; [@kfx035-B23]; [@kfx035-B32]; [@kfx035-B53]; [@kfx035-B52]; [@kfx035-B68]; [@kfx035-B77]).

Despite the toxicity of PAHs, the overall toxicity or mutagenicity of complex environmental mixtures often cannot be explained by PAHs alone ([@kfx035-B9]; [@kfx035-B70]). This has led to an increasing interest in PAH derivatives, including oxygenated PAHs (OPAHs), nitrated PAHs (NPAHs) and heterocyclic PAHs (HPAHs), which contain one or more heteroatomic substitutions within or on the aromatic ring system. These PAH derivatives are less studied than the corresponding unsubstituted, or parent, PAHs, both with regards to toxicity and environmental occurrence.

PAH derivatives can occur in the environment from a range of primary and secondary sources, including biotic and abiotic transformation processes ([@kfx035-B11]; [@kfx035-B42]; [@kfx035-B66]; [@kfx035-B75]; [@kfx035-B76]). NPAHs are known to be formed through reactions with particulate-bound PAHs and NO~x~ radicals during atmospheric transport ([@kfx035-B1]; [@kfx035-B35]; [@kfx035-B79]), as well as being common pollutants in diesel vehicle exhaust ([@kfx035-B3]; [@kfx035-B62]). Both NPAHs and HPAHs are also known constituents of petroleum-based products, such as sealcoat pavement sealant ([@kfx035-B69]; [@kfx035-B76]).

Limited toxicological data exists for NPAHs and HPAHs, most of which has been focused on mutagenicity. Many NPAHs and HPAHs are highly mutagenic in the Ames Salmonella assay ([@kfx035-B2]; [@kfx035-B34]; [@kfx035-B60]), and several NPAHs are known or suspected human carcinogens ([@kfx035-B59]; [@kfx035-B77]).

Limited data exists for NPAHs and HPAHs with other acute or developmental toxicity endpoints. However, these studies have been limited in the number of compounds investigated, or the non-mortality endpoints observed, leading to a lack of comparable information across a large set of compounds ([@kfx035-B14]; [@kfx035-B33]; [@kfx035-B50]; [@kfx035-B51]).

Aromatic compounds, such as PAHs, are well-known and established to activate the aryl hydrocarbon receptor (AHR) pathway and, in many cases, the observed toxicity is *AHR*-dependent ([@kfx035-B21]; [@kfx035-B40]; [@kfx035-B56]). Binding of a ligand, such as a PAH, to the AHR results in up-regulation of numerous downstream genes, including the cytochrome P450s (*cyp* genes), which metabolize certain AHR ligands, including PAHs ([@kfx035-B13]; [@kfx035-B46]; [@kfx035-B61]).

Other mechanisms of action for PAHs and PAH-containing mixtures have also been commonly observed, including oxidative stress and cardiac stress. Oxidative stress pathways are known to be linked with activation of the AHR pathway ([@kfx035-B12]), and AHR knockout mice have a reduced ability to generate an antioxidant response following exposure to TCDD, a known AHR agonist ([@kfx035-B65]). Cardiac toxicity following exposure to 5-ring PAHs can be mediated by the AHR pathway, but these effects were AHR-independent for other structurally similar compounds ([@kfx035-B7]; [@kfx035-B30]; [@kfx035-B64]). Cardiac toxicity is also commonly observed following exposure to PAH-containing mixtures ([@kfx035-B24]; [@kfx035-B37]).

Zebrafish (*Danio rerio*) are an increasingly popular model system for high-throughput screening of compounds for developmental toxicity and mechanistic investigations ([@kfx035-B16]). Zebrafish embryos develop rapidly and externally, with their major organs and systems formed within 5 days post-fertilization, and are amenable to cell culture techniques, including growth in 96-well tissue culture plates ([@kfx035-B8]; [@kfx035-B36]; [@kfx035-B43]; [@kfx035-B48]; [@kfx035-B73]). Developing zebrafish embryos have a high degree of homology to humans, and this model has previously been used for the evaluation of PAH and OPAH toxicity ([@kfx035-B7]; [@kfx035-B26]; [@kfx035-B27]; [@kfx035-B28]; [@kfx035-B40]; [@kfx035-B41]).

The goal of this study was to determine the developmental toxicity of a suite of NPAHs and HPAHs using the embryonic zebrafish model. In addition to the developmental toxicity screen, potential mechanisms of action for NPAH and HPAH toxicity were investigated, including activation of the AHR pathway, oxidative stress, and cardiac stress.

MATERIALS AND METHODS
=====================

### 

#### Fish Care and Husbandry

Adult zebrafish were maintained with a water temperature of 28° ±1 °C on a recirculating system with a 14h light: 10h dark photoperiod at the Sinnhuber Aquatic Research Laboratory (SARL). All experiments were conducted with the wild type Troptical 5D strain or *Tg(cyp1a:nls-egfp)* (background strain TL) zebrafish ([@kfx035-B39]). Adult care and reproductive techniques were conducted according to the Institutional Animal Care and Use Committee protocols at Oregon State University (OSU). All 5D embryos used in exposures were collected following group spawning of adult zebrafish as described previously ([@kfx035-B58]). Embryos from the *Tg(cyp1a:nls-egfp)* reporter line were collected following incross or outcross small group spawns.

#### Chemicals and Developmental Exposures

Analytical-grade standards were obtained from several vendors, including Sigma (St. Louis, MO), AccuStandard (New Haven, CT) and Chiron AS (Trondheim, Norway). Dimethyl sulfoxide (DMSO) was obtained from Sigma. Two compounds, 7-nitrobenzo\[k\]fluoranthene and 3,7-dinitrobenzo\[k\]fluoranthene, were custom synthesized in-house at OSU ([@kfx035-B34]). For a complete list of chemicals tested, see [Supplementary Data](#sup1){ref-type="supplementary-material"} (SD) 1. In total, 27 NPAHs, two amino PAHs (potential metabolites of NPAHs), and 10 heterocyclic PAHs were tested. Individual compounds were dissolved in DMSO to make stock concentrations of either 10 or 1 mM, dependent on solubility (concentrations are listed in SD 1). For the static exposures to zebrafish, compounds were dispensed into polystyrene 96-well plates pre-loaded with 100 µl of embryo media and individual zebrafish embryos, which had been enzymatically dechorionated and loaded into the plates using automation ([@kfx035-B44]). Chemicals were dispensed into the plates using an HP D300 Digital Dispenser and shaken using pre-optimized protocols ([@kfx035-B69]; [@kfx035-B71]). Two plates were treated with each chemical at a range of initial exposure concentrations (50, 35.6, 11.2, 5, 1.12 µM for chemicals with a 10 mM DMSO stock, or 5, 3.56, 1.12, 0.5, 0.1 µM for chemicals with a 1 mM DMSO stock), for a total number of 32 animals exposed to each concentration. 1% DMSO vehicle controls were also exposed on each plate. Following chemical addition, plates were moved to a temperature-controlled room (28 °C) and were placed on a custom-modified rotating shaker table overnight ([@kfx035-B71]). Embryos were evaluated at 24 hpf for developmental progress, spontaneous movement, notochord malformations and mortality. At 120 hpf, embryos were screened for total mortality and a suite of morphological endpoints, including pericardial and yolk sac edemas, malformations of the eye, snout, jaw, pectoral and caudal fins, axial malformations, and touch response ([@kfx035-B40]; [@kfx035-B72]). Compounds were bi-hierarchically clustered based on similar malformation profiles using the "aheatmap" function in the NMF R package, in order to better evaluate structure-activity relationships.

#### Cyp1a/GFP Reporter Fish

For CYP1A evaluation using the *Tg(cyp1a:nls-egfp)* transgenic reporter fish ([@kfx035-B39]), 8--12 embryos per compound for all 39 compounds were exposed as described previously in section 2.2, to a single concentration selected to maximize malformations **whereas** minimizing mortality. Concentrations evaluated are listed in SD 1. Following chemical addition using the HP D300 Digital Dispenser, plates were shaken overnight as described in section 2.2. Embryos were evaluated following continuous chemical exposure at 48 (prior to liver development and metabolic capacity) and 120 hpf for *cyp1a/*GFP expression using a Keyence BZ-X700 fluorescence microscope (Keyence North America, Itasca, IL). The *cyp1a*/GFP reporter line harbors a fosmid construct with GFP under control of a recombineered zebrafish *cyp1a* promoter, and recapitulates *cyp1a* induction by TCDD with high sensitivity ([@kfx035-B39]). Immunohistochemistry (IHC) was also performed for all compounds following exposure in the wild type 5D zebrafish from 6--120 hpf to validate results from the reporter line. Further information can be found in SD 2.

#### Antisense Morpholino Injections

Morpholinos designed against zebrafish AHR1A, AHR1B, and AHR2, as well as a standard injection control morpholino were purchased from Gene Tools (Philomath, OR), and sequences are provided in [Table 1](#kfx035-T1){ref-type="table"} ([@kfx035-B17]; [@kfx035-B20]). Morpholinos were dissolved in ultrapure water, and heterozygous *Tg(cyp1a:nls-egfp)* transgenic reporter embryos were injected at the 1--2 cell stage with 2 nL of morpholino (concentrations give in [Table 1](#kfx035-T1){ref-type="table"}) and 0.5% phenol red. Embryos developing normally with morpholino incorporation were exposed to single concentrations of selected compounds, representing each of the previously observed *cyp1a*/GFP expression patterns: 5-nitroacenaphthalene, 1,6-dinitropyrene, 1,3-dinitropyrene, 7-nitrobenzo\[k\]fluoranthene, 9-nitrophenanthrene, 7-nitrobenz\[a\]anthracene, 3-nitrofluoranthene, 3,7-dinitrodibenzo\[k\]fluoranthene, and DMSO. Embryos were chemically exposed from 6 to 48 or 6 to 120 hpf and imaged at 48 or 120 hpf, respectively, using a Keyence BZ-X700 fluorescence microscope, and evaluated for developmental toxicity and *cyp1a* expression. TABLE 1Sequences of Morpholino Oligonucleotides Used, with Appropriate Injection ConcentrationsAHR IsoformSequenceConcentrationAHR1ACTTTTGAAGTGACTTTTGGCCCGCA1.5 mMAHR1BACACAGTCGTCCATGATTACTTTGC0.75 mMAHR2TGTACCGATACCCGCCGACATGGTT0.75 mMControlCCTCTTACCTCAGTTACAATTTATA1.5 mMAHR1B/AHR2 mixture0.75 mM each

#### AHR Docking Predictions

Docking of individual compounds to *in silico* models of the Per-AHR/Arnt-Sim (PAS)-B domains of each of the zebrafish AHR isoforms, as well as human AHR, was performed as previously described ([@kfx035-B6]; [@kfx035-B19]; [@kfx035-B54]). Docking scores were assigned for each compound and AHR isoform, overall priority for docking to any AHR isoforms were assigned, and predictions were compared to *in vivo cyp1a*/GFP expression.

#### RNA Extraction

For RNA samples, dechorionated 5D embryos were exposed from 6 to 48 hpf or 6 to 120 hpf to a subset of NPAHs at the same concentration used for *Tg(cyp1a:nls-egfp)* transgenic reporter fish evaluations (SD 1). Compounds were selected for qPCR analysis in order to sample a range of developmental toxicities and AHR activation patterns: 5-nitroacenaphthalene, 1,6-dinitropyrene, 1,3-dinitropyrene, 7-nitrobenzo\[k\]fluoranthene, and vehicle control. Briefly, 48 hpf or 120 hpf embryos were rinsed in embryo media and four samples of 20 embryos each were collected on ice in snap-safe Eppendorf tubes with 0.5 mm zirconium oxide beads. 500 μl RNAzol was added and samples were homogenized with a Bullet Blender (Next Advance) for 3 min at speed 8, and then stored at --20 °C until RNA isolation.

For total RNA isolation, RNA was extracted via RNAzol/isopropanol precipitation as previously described ([@kfx035-B40]). RNA was quantified using a Synergy/Mxmicroplate reader (Biotek) with the Gen5 Take3 module to calculate 260/280 O.D. ratios and RNA concentration. RNA was stored at --80 °C until use.

#### Quantitative RT-qPCR

Gene expression of a suite of 21 AHR-related, cardiac stress-related and oxidative stress gene transcripts was assessed in whole-embryo homogenates for 6--48 hpf or 6--120 hpf exposures of single concentrations of selected compounds (listed in Section 2.4). Gene-specific primers (MWG Operon) are listed in SD 3. All qRT-PCR experiments were performed in 10 µl reactions consisting of 5 µl Power SYBR Green PCR one-step master mix (Applied Biosystems), 0.4 µl of each 10 mM primer in 0.1% Triton X, 4.2 µl H~2~O and 2 µg of cDNA in 0.1% Triton X, which were dispensed using the PCR program on the HP D300 Digital Dispenser. The temperature program consisted of 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 58 or 60 °C (dependent on primer set), with a final melt curve consisting of a 15 s hold at 95 °C, 2 min at 70 °C, and a 0.2 °C per minute ramp, with a final hold at 95 °C for 15 s.

#### Statistics and Data Analysis

##### Data analysis

Statistical analysis and data visualization for developmental toxicity screening was done using code developed in R, using the custom Zebrafish Analysis and Acquisition (ZAAP) program ([@kfx035-B73]). Concentrations which induced 50 percent effect (EC~50~) were calculated by fitting dose-response data with a binomial logit regression using custom R scripts and the *dose.p* function ([@kfx035-B22]; [@kfx035-B57]). Venn diagram representations of *cyp1a*/GFP expression patterns were generated using the Draw Venn Diagrams software from the Ghent University Bioinformatics Evolutionary Genomics group.

##### PCR statistics

qRT-PCR analysis was performed with StepOne software (Applied Biosystems), using the Δ ΔC~T~ method with genes normalized to β-actin ([@kfx035-B55]). Four biological replicates of 20 embryos each were analyzed by comparing NPAH treated to DMSO control with a one-way ANOVA following normalization with β-actin, using SigmaPlot V11.0 software.

RESULTS
=======

### Developmental Toxicity Screen

Concentration-dependent morphological responses were observed at 24 hpf and 120 hpf in the zebrafish embryos exposed to a dilution series of NPAHs and HPAHs, compared to the DMSO-exposed control, for which no significant developmental toxicity was observed. This data is presented in [Figure 1](#kfx035-F1){ref-type="fig"} as a heatmap, showing the relative potency derived from the lowest effect level (LEL) value for each endpoint evaluated, as well as any effect including and excluding mortality, for each compound tested. FIG. 1Heatmap displaying developmental toxicity of all 39 compounds investigated. Color scaling indicates relative potency, based on the lowest effect level (LEL) observed for a given compound and endpoint. Darker shades of green indicate a higher relative potency, and therefore a more toxic response, whereas lighter shades indicate a lower relative potency and less toxic response. White indicates that there was no significant observable LEL for that endpoint, or that values were incalculable due to high mortality. Compounds are vertically clustered based on the observation of similar developmental endpoints. Groups of compounds with similar toxicity profiles are indicated by boxes and group numbers.

Based on the clustering of compounds with similar developmental toxicity endpoints, several groups of compounds, with similar toxicity profiles and commonly observed endpoints, emerged. The most toxic group of compounds, as indicated by lowest effect levels at the lowest concentrations, were 3-nitrobenzanthrone, 1,6-dinitropyrene, and 1,3-dinitropyrene (labeled as group 1 in [Figure 1](#kfx035-F1){ref-type="fig"}), which caused the common endpoints of pericardial and yolk sac edemas and craniofacial malformations at 120 hpf with high potency. Similar endpoints, in addition to mortality at 24 hpf, were observed for 1-aminopyrene, acridine, and 5,6-benzoquinoline (group 2). However, for this group of compounds, these effects were observed at higher concentrations. The next group of compounds included 5-nitroacenaphthalene, 9-nitrophenanthrene, and 1,8-dinitropyrene (group 3), displayed a higher degree of lethality and a lower incidence of non-mortality endpoints, at relatively higher concentrations. The next group of chemicals (9-aminophenanthrene, 7-nitrobenz\[a\]anthracene, carbazole, and 2-nitroanthracene; group 4) resulted in stronger effects at 24 hpf, including developmental delay and mortality, as well as pericardial edema at 120 hpf. Defects in circulation, marked by pooling of blood in the body of the zebrafish embryos, was the only endpoint observed following exposure to 1-nitropyrene and 3-nitrofluoranthene (group 5). Two compounds (2-nitropyrene and dibenzofuran; group 6) had a significant effect for the "any effect" or "any effect including mortality" endpoints, but not for any of the individual endpoints. The remaining 22 compounds (group 7), greater than half of those tested, did not result in significant toxicity to the zebrafish embryos following exposure at the tested concentrations.

The EC~50~ values were calculated for compounds with observed toxicity and are shown in [Table 2](#kfx035-T2){ref-type="table"}. Values ranged from 0.096 µM (1,3-dinitropyrene) to 44.8 µM (1-nitropyrene). Three compounds (2-nitroanthracene, 7-nitrobenz\[a\]anthracene, and dibenzofuran) had EC~50~ values estimated to be beyond the tested range of concentrations, and beyond the range of accuracy of the EC~50~ model. TABLE 2EC~50~ (µM) Values for All Compounds, With Standard ErrorEC~50~ (µM)Std Error**NPAHs**--------1-nitronaphthalene--------2-nitronaphthalene--------2-nitrobiphenyl--------3-nitrobiphenyl--------4-nitrobiphenyl--------3-nitrodibenzofuran--------5-nitroacenaphthalene13.410.782-nitrofluorene--------9-nitroanthracene222.13^†^1899-nitrophenanthrene1.810.782-nitrodibenzothiophene--------3-nitrophenanthrene--------2-nitroanthracene--------2-nitrofluoranthene--------3-nitrofluoranthene2.040.851-nitropyrene44.828.342-nitropyrene--------7-nitrobenz\[a\]anthracene237.6^†^1082,8-dinitrodibenzothiophene--------6-nitrochrysene--------3-nitrobenzanthrone0.20.171,3-dinitropyrene0.10.051,6-dinitropyrene0.880.221,8-dinitropyrene3.331.186-nitrobenzo\[a\]pyrene--------7-nitrobenzo\[k\]fluoranthene--------3,7-dinitrobenzo\[k\]fluoranthene--------**Amino PAHs**1-aminopyrene1.850.749-aminophenanthrene8.680.87**HPAHs**Indole--------Quinoline--------2-Methylbenzofuran--------Thianaphthene--------8-Methylquinoline--------Carbazole15.150.96Dibenzofuran228.3[^a^](#tblfn2){ref-type="table-fn"}227.45,6-Benzoquinoline10.351.04Acridine13.490.96Xanthene--------[^1][^2]

### CYP Expression as a Biomarker for AHR Pathway Activation

To investigate the potential role of AHR, we utilized the transgenic *Tg(cyp1a:nls-egfp)* zebrafish line to evaluate expression of *cyp1a*/GFP, a known biomarker for AHR activation. Several distinct *cyp1a*/GFP expression patterns were observed following exposure to each of the 39 individual compounds from samples collected at 48 and 120 hpf ([Figure 2](#kfx035-F2){ref-type="fig"}). Compared to the DMSO-exposed control in which no distinct *cyp1a*/GFP expression was observed ([Figure 2A](#kfx035-F2){ref-type="fig"}), *cyp1a*/GFP expression was observed in the liver ([Figure 2B](#kfx035-F2){ref-type="fig"}), vasculature ([Figure 2C](#kfx035-F2){ref-type="fig"}), yolk sac ([Figure 2D](#kfx035-F2){ref-type="fig"}), skin, and neuromasts ([Figure 2E](#kfx035-F2){ref-type="fig"}) following exposure to certain NPAHs. There were also a number of compounds for which no *cyp1a*/GFP expression was observed. Tissues displaying fluorescence, indicating *cyp1a*/GFP expression and activation of the AHR pathway, for all compounds tested are listed in [Table 3](#kfx035-T3){ref-type="table"}. Several compounds also showed *cyp1a*/GFP expression in multiple tissues simultaneously. For example, expression in the neuromasts was always observed alongside expression in the skin. Unique and overlapping *cyp1a*/GFP expression patterns are shown in Venn diagrams, for expression at 48 hpf ([Figure 2F](#kfx035-F2){ref-type="fig"}) and 120 hpf ([Figure 2G](#kfx035-F2){ref-type="fig"}). FIG. 2Selected representative images of *cyp1a*/GPF expression in *Tg(cyp1a:nls-egfp)* transgenic zebrafish following chemical exposures. Examples of *cyp1a*/GFP expression patterns in the DMSO-exposed animals (A), liver (B), vasculature (C), yolk sac (D) and skin, neuromasts and liver (E) following exposure to indicated NPAHs. Expression patterns observed at 48 hpf (F) and 120 hpf (G), showing unique and overlapping *cyp1a*/GFP expression patterns for all compounds where expression in one or more tissues was observed. All results are summarized in [Table 3](#kfx035-T3){ref-type="table"}.TABLE 3Summary of *cyp1a*/GFP expression Patterns Observed Using *Tg(cyp1a:nls-egfp)* Transgenic Zebrafish Following Individual Exposure to all NPAHs and HPAHs Studied, at 48 hpf and 120 hpf48 hpf120 hpf**NPAHsLiverVasculatureYolkSkinNeuromastNoneLiverVasculatureYolkSkinNeuromastNone**1-nitronaphthalene--------------------x--------------------x2-nitronaphthalene--------------------x--------------------x2-nitrobiphenyl--------------------x--------------------x3-nitrobiphenyl--------------------xx--------------------4-nitrobiphenyl--------------------x--------------------x3-nitrodibenzofuran--------------------x--------------------x5-nitroacenaphthalene--------------------xx--------------------2-nitrofluorene--------------------x--------------------x9-nitroanthracene--------------------x--------------------x9-nitrophenanthrene--------------------xx--------------------2-nitrodibenzothiophene--------------------xx--------------------3-nitrophenanthrene--------------------xx--------------------2-nitroanthracene--------x--------------------x------------2-nitrofluoranthene----x----x--------xxx------------3-nitrofluoranthene--------------------x----xx------------1-nitropyrene--------------------x--------x------------2-nitropyrene--------------------x--------------------x7-nitrobenz\[a\]anthracene------------x------------x----x--------2,8-dinitrodibenzothiophene--------------------x--------------------x6-nitrochrysene------------x------------x----x--------3-nitrobenzanthrone--------xx----------------x------------1,3-dinitropyrene--------------------x--------x------------1,6-dinitropyrene------------x------------x----x--------1,8-dinitropyrene--------------------x--------------------x6-nitrobenzo\[a\]pyrene--------------------xxx----x--------7-nitrobenzo\[k\]fluoranthene------------x--------xx----xx----3,7-dinitrobenzo\[k\]fluoranthene--------------------x----x----xx----**Amino PAHs**----------------------------1-aminopyrene--------------------x----xx------------9-aminophenanthrene--------------------xx--------------------**HPAHs**------------------------------------------------Indole------------x------------x----xx----Quinoline--------------------x--------------------x2-Methylbenzofuran--------------------x--------------------xThianaphthene--------------------x--------------------x8-Methylquinoline--------------------x--------------------xCarbazole--------------------xxx----------------Dibenzofuran--------------------x--------------------x5,6-Benzoquinoline------------x--------x--------x--------Acridine----x----x--------x----------------xXanthene--------------------xx[^3]

### Knock-Down of AHR to Elucidate its Role in Developmental Toxicity

Embryos injected with any of the morpholinos did not display an increase in background developmental toxicity, compared to non-injected controls (data not shown). *cyp1a*/GFP expression in the livers of fish exposed to 5-nitroacenaphthalene, 9-nitrophenanthrene, and 7-nitrobenzo\[k\]fluoranthene was eliminated in AHR1A morphants ([Figs. 3B--C](#kfx035-F3){ref-type="fig"}), but did not result in a substantial decrease in observed developmental toxicity following exposure to 5-nitroacenaphthalene. FIG. 3Selected representative images of *cyp1a*/GPF expression in *Tg(cyp1a:nls-egfp)* transgenic zebrafish following chemical exposures and morpholino oligonucleotide injections. Examples of *cyp1a*/GFP expression patterns in the DMSO-exposed animals (A), liver (B), absence liver expression in AHR1A morphants (C), skin, neuromasts and liver (D), near-complete elimination of skin, neuromast, and vascular expression in AHR2 morphants (E), and complete skin, neuromast, and vasculature expression elimination (F) following co-injection of the AHR2 and AHR1B morpholinos, following exposure to indicated NPAHs.

Decreased GFP expression in AHR2 morphants *cyp1a*/GFP reporter embryos exposed to 7-nitrobenzo\[k\]fluoranthene in the skin and neuromasts, and 7-nitrobenz\[a\]anthracene in the vasculature, indicating AHR2 dependence for *cyp1a*/GFP expression ([Figs. 3D--E](#kfx035-F3){ref-type="fig"}), at both 48 and 120 hpf. Expression in the skin and vasculature following exposure to 1,6-dinitropyrene and 3,7-dinitrobenzo\[k\]fluoranthene were also reduced in AHR2 morphants (not shown). Injection of the AHR1B morpholino alone did not visibly reduce *cyp1a*/GFP expression following exposure to any of the compounds investigated. However, co-injection of AHR2 and AHR1B morpholinos appeared to reduce GFP expression slightly more than the AHR2 morpholino alone ([Figure 3F](#kfx035-F3){ref-type="fig"}).

### *In Silico* Docking to AHR Active Site Models

Of the set of 39 compounds investigated, 22 were predicted to dock to one or more isoforms of the zebrafish AHR. [Table 4](#kfx035-T4){ref-type="table"} shows the docking scores, (given in kilocalories/mol), for all three zebrafish AHR isoforms, as well as human AHR, along with the overall docking priority to the zebrafish AHR isoforms. The more negative the docking score, the higher the predicted binding and activation. Of the 22 compounds predicted to dock to one or more isoforms of the zebrafish AHR, 16 displayed *in vivo cyp1a*/GFP expression, indicative of AHR activation, for a success rate of 73%. Of the 23 compounds which showed *in vivo cyp1a*/GFP expression, 16 were predicted to dock to the AHR, for a success rate of 70%. TABLE 4Predicted AHR Docking Scores (kilocalories/mol) for All Three Zebrafish AHR Isoforms, as Well as Human AHRDocking Scores**NPAHsHumanZebrafish AHR2Zebrafish AHR 1BZebrafiah AHR1AHigh Priority**1-nitronaphthalene--14.32--16.08--13.01--19.362-nitronaphthalene--13.43--14.78--18.03--17.972-nitrobiphenyl--11.83--15.5--19.13--15.433-nitrobiphenyl--14.94--17.73--18.01--15.424-nitrobiphenyl--18.12--12.71--14.19--17.23-nitrodibenzofuran--19.52--19.09--14.9--18.07†5-nitroacenaphthalene--5.91--11.29--15.46--17.04†2-nitrofluorene--12.97--9.1--9.72--17.07†9-nitroanthracene--9.89--10.15--12.06--14.84†9-nitrophenanthrene--3.08--12.25--15.91[\*](#tblfn6){ref-type="table-fn"}--15.72†2-nitrodibenzothiophene--15.85--17.06--10.85--17.92†3-nitrophenanthrene--12.91--15.17--16.31[\*](#tblfn6){ref-type="table-fn"}--16.34†2-nitroanthracene--16.55--14.81--8.2--19.02†2-nitrofluoranthene--8.33--12.79--15.25[\*](#tblfn6){ref-type="table-fn"}--12.433-nitrofluoranthene--9.12--7.91--16.55[\*](#tblfn6){ref-type="table-fn"}--17.14†1-nitropyreneND--6.91--15.67[\*](#tblfn6){ref-type="table-fn"}--12.07†2-nitropyrene--3.54--4.4--14.36[\*](#tblfn6){ref-type="table-fn"}--17.927-nitrobenz\[a\]anthracene--9.97--5.53--18.08[\*](#tblfn6){ref-type="table-fn"}ND†2,8-dinitrodibenzothiophene--15.14--18.19--10.85--17.31†6-nitrochrysene--11.37--5.47--16.91[\*](#tblfn6){ref-type="table-fn"}--11.6†3-nitrobenzanthrone--5.64--3.86--17.15[\*](#tblfn6){ref-type="table-fn"}--6.66†1,3-dinitropyreneNDND--15.13[\*](#tblfn6){ref-type="table-fn"}ND1,6-dinitropyreneND--5.71--15.85[\*](#tblfn6){ref-type="table-fn"}ND1,8-dinitropyrene--3.69--5.66--16.23[\*](#tblfn6){ref-type="table-fn"}--11.646-nitrobenzo\[a\]pyreneND--1.64--18.13[\*](#tblfn6){ref-type="table-fn"}ND7-nitrobenzo\[k\]fluoranthene--5.27ND--16.05[\*](#tblfn6){ref-type="table-fn"}ND3,7-dinitrobenzo\[k\]fluoranthene--5.27ND--16.05[\*](#tblfn6){ref-type="table-fn"}ND**Amino PAHs**1-aminopyreneND--5.3--15.06[\*](#tblfn6){ref-type="table-fn"}--11.09†9-aminophenanthrene--7.77--10.99--11.89--21.81†**HPAHs**Indole--11.14--15.57--13.94--19.94†Quinoline--12.29--15.18--17.52--15.832-Methylbenzofuran--15.38--17.2--16.96--14.17Thianaphthene--13.89--12.07--14.46--17.78-Methylquinoline--7.85--13.23--12.8--17.29Carbazole--11.86--14.85--15.81--19.78†Dibenzofuran--15.02--15.82--14.07--16.12†5,6-Benzoquinoline--14.18--11.97--14.57--20.46†Acridine--15.68--15.48--11.31--15.09†Xanthene--16.26--14.69--11.64--14.18†[^4][^5][^6]

### Differential Gene Expression to Elucidate Other Potential Mechanisms of Action

To further investigate other potential mechanisms of action for NPAHs, qPCR analysis was performed for a suite of 21 genes selected to investigate cardiac toxicity, oxidative stress, and additional potential mechanisms of action. Significantly increased expression of *cyp1a*, *cyp1b1*, *cyp1c1*, and *cyp1c2* was observed following exposure to 5 µM 1,6-dinitropyrene at 48 and 120 hpf, and at 120 hpf following exposure to 50 µM 7-nitrobenzo\[k\]fluoranthene for *cyp1a*, *cyp1b1*, and *cyp1c1* ([Figure 4A--B](#kfx035-F4){ref-type="fig"}). Expression of *cyp1a1* at 48 hpf was increased by 1,963-fold following exposure to 1,6-dinitropyrene, compared to the DMSO exposed controls. In the genes related to cardiac stress, expression of *nppb* (natriuretic peptide b, which encodes a small peptide responsible for the regulation of homeostatic contractility and response to cardiac stress) was increased by 12-fold in animals exposed to 1.12 µM 1,8-dinitropyrene at 48 hpf, and 23-fold in animals exposed to 3.56 µM 1,3-dinitropyrene at 120 hpf. Additionally, expression of *myl6* (cardiac myosin light chain 6, which encodes the essential cardiac myosin light chain) was significantly decreased by 0.9-fold in the 1,8-dinitropyrene exposed animals at 48 hpf, whereas expression of *myl7* (cardiac myosin light chain 7, which encodes the regulatory cardiac myosin light chain) was significantly increased by 2-fold in animals exposed to 1,3-dinitropyrene at 48 hpf ([Figure 4C--D](#kfx035-F4){ref-type="fig"}). Other genes important in detoxification and cellular protection from oxidative stress were also differentially expressed following developmental exposure to NPAHs ([Figure 4E](#kfx035-F4){ref-type="fig"}, SD 3). These included members of the superoxide dismutase (*sod*) family (an antioxidant enzyme responsible for the dismutation of superoxide radical into molecular oxygen or hydrogen peroxide), glutathione transferases (*gst*, phase II enzymes responsible for the conjugation of reduced glutathione to xenobiotic substrates), and glutathione peroxidases (*gpx*, which protect against oxidative stress by reducing peroxides). 1,3-dinitropyrene at 48 hpf resulted in differential expression of the greatest number of genes (4), **whereas***arg2* (arginase) was the gene most commonly mis-expressed at both 48 hpf and 120 hpf. FIG. 4Changes in gene expression induced by exposure to selected NPAHs. Graphs indicate changes in expression to selected *cyp* genes at 48 hpf (A) and 120 hpf (B), and in selected cardiac stress genes at 48 hpf (C) and 120 hpf (D). Asterisks indicate statistical significant at a *P *\<* *0.05 level, based on one-way ANOVA. All genes investigated are shown in the heatmap (E) for 48 and 120 hpf, where color scaling indicates increased or decreased expression.

DISCUSSION
==========

Whereas unsubstituted PAHs are known to elicit a range of human and environmental health effects, NPAHs and HPAHs are not as thoroughly studied. Investigation of the developmental toxicity of these compounds, as well as potential contributing mechanisms of action, is important in order to more accurately determine potential human and environmental health hazards as a result of exposure. A range of developmental toxicity endpoints and *cyp1a*/GFP expression patterns were observed following NPAH or HPAH exposure. Selected compounds also resulted in a variety of differentially expressed genes, indicating multiple potential contributing mechanisms of action.

Differential Developmental Toxicity
-----------------------------------

Of the 39 compounds screened, 17 (44%) resulted in significant developmental toxicity of at least one observed endpoint. The profile of developmental toxicity malformations observed is similar to what has been previously observed with PAHs and oxygenated PAHs, as well as PAH-containing oil preparations ([@kfx035-B21]; [@kfx035-B31]; [@kfx035-B37]; [@kfx035-B40]).

Comparing the calculated EC~50~ values with the log *K*~ow~, molecular weight, and water solubility of compounds tested did not result in any significant correlation (SD 1). However, experimentally derived values for the log *K*~ow~ and water solubility do not exist for many of the compounds in this data set, resulting in a reliance on estimated values from the EPI Suite program ([@kfx035-B74]). Previous studies had shown relationships between the observed toxicity of N-heterocyclic ([@kfx035-B63]) and substituted anilines ([@kfx035-B80]) with molecular weight, partition coefficients, and/or bioconcentration factors; however, experimentally determined values were available for the compounds under investigation in those studies. The reliability of our modeling would likely be improved if experimentally determined values had been available.

There is also significant uncertainly in the aqueous concentrations and uptake of these compounds during the assay. Sorption of hydrophobic analytes to the polystyrene plates commonly used for zebrafish testing is known to occur, and can result in significant analyte loss, with upwards of 50 percent of the analyte sorbing to the plastic rather than remaining in the aqueous exposure media ([@kfx035-B10]; [@kfx035-B51]). Whereas the protocols have been optimized to minimize the sorptive losses which occur ([@kfx035-B71]), and maximize the analyte concentration in the exposure solution, the actual analyte concentration remaining in the exposure media is uncertain. Furthermore, the availability and uptake of PAHs and PAH derivatives can be variable ([@kfx035-B21]), and is unknown for the NPAHs and HPAHs studied here.

Activation of the AHR Pathway and cyp1a Expression
--------------------------------------------------

Fluorescence indicating *cyp1a* expression and activation of one or more AHR isoforms was observed at 48 and/or 120 hpf for 23 of the 39 compounds tested, suggesting the involvement of AHR in the toxicity of at least some NPAHs and HPAHs. Other mechanisms for the induction of *cyp1a*, such as cellular stress, could potentially be contributing as well ([@kfx035-B4]), but the selective elimination of c*yp1a*/GFP expression in AHR2 morphants suggests the AHR isoform dependence of *cyp1a* expression.

The near-complete inhibition of *cyp1a*/GFP expression in the vasculature and/or skin (and neuromasts, for 7-nitrobenzo\[k\]fluoranthene) of embryos exposed to 7-nitrobenzo\[k\]fluoranthene, 1,6-dinitropyrene, 7-nitrobenz\[a\]anthracene and 3,7-dinitrobenzo\[k\]fluoranthene, following knockdown of AHR2, indicates that AHR2 is the primary isoform responsible for expression in these tissues. Decreased toxicity was observed in 1,6-dinitropyrene exposed AHR2 morphants, indicating a role for AHR in the toxicity of this compound. No substantial change in toxicity was observed for the other three compounds investigated, which were all relatively non-toxic in the developmental toxicity screen. This is consistent with previous research on PAHs and oxygenated PAHs, where knockdown of AHR2 results in the inhibition of the skin or vasculature *cyp1a*/GFP expression patterns ([@kfx035-B21]; [@kfx035-B30]; [@kfx035-B40]). Expression of *cyp1a* has been observed previously in the neuromasts of transgenic Japanese Medaka (*Oryzias latipes*) following exposure to TCDD ([@kfx035-B47]), although no further mechanistic information has been elucidated. Based on our results, the inhibition of *cyp1a*/GFP expression in the neuromasts, in AHR2 morphants, indicates AHR2 dependence of this expression pattern as well.

The decrease in *cyp1a*/GFP expression in AHR1A morphants is also consistent with previous research ([@kfx035-B40]), which implicated AHR1A as the dominant isoform present in the liver. Fluorescence in the liver was not observed in 48 hpf embryos, due to the majority of liver development occurring after 48 hpf ([@kfx035-B49]). We did not observe a substantial decrease in toxicity in AHR1A morphants, indicating that the toxicity observed is not completely AHR-dependent.

*cyp1a*/GFP expression in the yolk of embryos exposed to 1,3-dinitropyrene or 3-nitrofluoranthene did not appear to decrease as a result of injection with any of the morpholinos. *cyp1a*/GFP expression in the syncytial layer of the yolk had been previously observed following exposure to 1,9-benz-10-anthrone ([@kfx035-B19]), although this was not determined to be due to a specific isoform of the AHR. Another isoform of *cyp*, *cyp11a1*, is expressed in the yolk syncytial layer ([@kfx035-B18]; [@kfx035-B25]), although this isoform has not been linked with xenobiotic metabolism.

Overall, the *in silico* model for the AHR1A isoform had the highest predictive success rate, where eight of the 12 compounds with *in vivo cyp1a*/GFP expression were predicted to dock to the AHR, in most cases to the AHR1A with the highest affinity. In contrast, the predicted docking scores to the AHR2 isoform did not align well with the observed *cyp1a*/GFP expression patterns in the skin and vasculature. The AHR docking models were developed and refined using TCDD as the guide ligand for AHR2 and AHR1B, and leflunomide for AHR1A ([@kfx035-B17]). Both TCDD and leflunomide are structurally distinct from PAHs. Whereas the AHR docking models performed adequately for the NPAHs and HPAHs studied here, there is room for further optimization of these models for PAHs and PAH derivatives, in particular the larger and more potent compounds. Binding to the different isoforms of the AHR appears to be the major factor contributing to the differential *cyp1a*/GFP expression patterns. Bioavailability and uptake for hydrophobic compounds can vary greatly and is not known for NPAHs and HPAHs, the larger and more hydrophobic compounds, such as 7-nitrobenzo\[k\]fluoranthene and the dinitropyrenes were among the most potent both with regards to *cyp1a*/GFP expression and developmental toxicity, suggesting that bioavailability and uptake is not necessarily a limiting factor for bioactivity of these compounds.

NPAHs Differentially Alter Gene Expression
------------------------------------------

PAH and oxygenated PAH exposures have been previously linked with alterations in the expression of genes related to phase I metabolism (*cyp* genes), Phase II metabolism and oxidative stress, and cardiac toxicity ([@kfx035-B19]; [@kfx035-B26]; [@kfx035-B27]; [@kfx035-B28]; [@kfx035-B40]). Compared to oxygenated PAHs, fewer of the NPAHs studied resulted in significantly altered expression of the four *cyp* genes investigated. However, the induction was a similar order of magnitude. This could indicate that phase I metabolism by the *cyp* genes as a result of AHR activation is not a major detoxification pathway for many NPAHs. Whereas our data do suggest that the *cyp* metabolism pathways and phase II metabolism and oxidative stress could contribute to the toxicity of NPAHs, other mechanisms of action are likely also contributing. Metabolism and oxidative stress may be regulated, at least in part, by the *AHR* pathway, but further studies would be required to confirm this.

Cardiac toxicity has been previously observed following exposure to PAHs and PAH-containing products ([@kfx035-B27]; [@kfx035-B29]; [@kfx035-B37]; [@kfx035-B45]). We observed altered expression of each of the three genes investigated (*nppb*, *myl6*, and *myl7*) following exposure to 1,8-dinitropyrene and 1,3-dinitropyrene at 48 and 120 hpf, indicating that cardiac toxicity may play a role in the developmental toxicity of at least some NPAHs. Zebrafish exposed to these compounds also displayed pericardial edema and circulatory malfunction (indicated by pooling of blood in the body). However, these malformations were also observed following exposure to other compounds which did not alter expression of these cardiac genes. Of these two compounds, only 1,3-dinitropyrene also resulted in altered *cyp1a* expression, indicated by visual expression in the yolk sac, which indicates that the observed cardiac toxicity is, at least in part, not AHR-dependent. Previous work has shown a diversity in cardiac toxicity mechanisms among PAHs acting as AHR agonists ([@kfx035-B7]). Therefore, investigation of a wider number of genes and toxicity phenotypes is necessary to more fully elucidate the role of cardiac toxicity in the observed developmental toxicity of NPAHs and HPAHs, as well as the role of the AHR pathway.

The gene most commonly differentially expressed following NPAH exposure was *arg2*, the gene encoding the protein arginase 2. Arginases catalyze the hydrolysis of the amino acid arginine to urea and ornithine, and has a role in nitric oxide and polyamine metabolism ([@kfx035-B15]). Arginase expression is positively correlated to expression of nitric oxide synthase (NOS), and, therefore, increased production of nitric oxide. Nitric oxide plays regulatory roles on various physiological and pathophysiological properties, including vascular and neurological functions ([@kfx035-B67]). We observed significantly decreased expression of *arg2* at 48 hpf following exposure to all seven NPAHs tested, and significantly increased expression at 120 hpf following exposure to 1,6-dinitropyrene, 5-nitroacenaphthalene, and 7-nitrobenzo\[k\]fluoranthene. Previous work ([@kfx035-B19]) showed that *arg2* expression was significantly elevated by 1,9-benz-10-anthrone, but not by benz\[a\]anthracene-7,12-dione, in 48 hpf embryos, and was dependent on AHR2. Whereas we did not investigate AHR dependency of gene expression, two of the three compounds which had elevated *arg2* expression at 120 hpf (1,6-dinitropyrene and 7-nitrobenzo\[k\]fluoranthene) also displayed AHR2-dependent *cyp1a* expression. However, since many of the compounds under investigation were not observed to be AHR2-agonists, the altered expression of *arg2* at 48 hpf appears to be via an AHR2-independent mechanism.

CONCLUSION
==========

NPAHs and HPAHs, like the more thoroughly-studied PAHs and oxygenated PAHs, are toxicologically a non-homogenous group of compounds in the developing zebrafish model, as summarized in SD 4. NPAHs and HPAHs can elicit a variety of developmental toxicity endpoints, at a range of concentrations, demonstrating potential for ecological and human health impacts. NPAH and HPAH exposure also resulted in a range of *cyp1a*/GFP expression patterns, indicative of differential activation of AHR isoforms. Select NPAHs caused altered gene expression of a diverse set of genes, suggesting contributions of several potential mechanisms of action, including cardiac stress, *cyp* metabolism pathways, and oxidative stress. When considering health risks from PAH-containing complex environmental mixtures, PAH derivatives, including NPAHs and HPAHs, should be included. Further research into the toxicity and mechanisms of action of these compounds is warranted.
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[^1]: Blank cells indicate insufficient data to calculate EC~50~.

[^2]: Indicates calculated value is beyond the range of concentrations tested, and beyond the range of accuracy of the EC~50~ model.

[^3]: Tissues where *cyp1a*/GFP expression are observed are designated with an "x".

[^4]: ND indicates the compound was not predicted to dock, or docked with non-favorable score/energy to the AHR active site model. Asterisk indicates that docking was predicted, but with an unfavorable pose in the active site, despite the promising binding energy. Compounds were classified as "high priority" for AHR activation (indicated by †) based on overall AHR binding favorability to the three zebrafish isoforms.

[^5]: ND, not docked or docked with non favorable score/energy.

[^6]: despite the promising number, docked with a non favorable pose (binding pattern).
